Review explores HPV link to esophageal cancer

Share this article:
Review Explores HPV Link to Higher Risk of Esophageal Cancer
Review Explores HPV Link to Higher Risk of Esophageal Cancer

(HealthDay News) -- The presence of human papillomavirus (HPV) DNA is associated with a three-fold higher risk of esophageal cancer, according to a study published online July 24 in PLOS ONE.

Surabhi S. Liyanage from the University of New South Wales in Sydney, and colleagues performed a meta-analysis of 21 case-control studies (with a total of 1,223 cases and 1,415 controls) that examined esophageal squamous cell carcinoma (OSCC) tissue for the presence of HPV DNA.

The researchers found that 35 percent of OSCC samples contained HPV DNA, indicating a significantly increased risk of OSCC with the presence of HPV (pooled odds ratio, 3.04). The association was stronger in regions with low to medium OSCC incidence (odds ratio, 4.65) than regions of high OSCC incidence (odds ratio, 2.65).

"This study is the most definitive contribution to date about a question which has defied answers for 30 years: the association of HPV with OSCC," Liyanage and colleagues conclude. "It further adds to the support of HPV vaccination as a cancer-preventing vaccine for children of both genders, to broaden the preventive targets of the vaccine."

Two authors disclosed financial ties to vaccine companies.

Full Text

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.